Ascentage Pharma (6855.HK) today announced that it has released preliminary results of olverembatinib (HQP1351) in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), in an Oral Presentation at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition (New Orleans, LA), marking the first data readout from the Read More ›

Ascentage Pharma (6855.HK)  today announced that it has released preliminary results from a global Phase II study of lisaftoclax (APG-2575), a key member of the company’s apoptosis-targeting pipeline, as a monotherapy or in combination with CALQUENCE® (acalabrutinib) or rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL), in an oral Read More ›

Ascentage Pharma (6855.HK) today announced that its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) to enter a Phase I study in patients with advanced solid tumors or hematologic malignancies. Following the recent clearance for the Read More ›

Ascentage Pharma (6855.HK) today announced that it has released results from a Phase I study of the investigational inhibitor of apoptosis protein (IAP) antagonist APG-1387 in Chinese patients with chronic hepatitis B (CHB), in an oral presentation at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). This is the Read More ›

Ascentage Pharma today announced that the updated results from three studies of the company’s novel drug candidate, olverembatinib (HQP1351), have been selected for oral presentations at the 64th American Society of Hematology (ASH) Annual Meeting. This is the fifth consecutive year in which studies of olverembatinib were selected for oral presentations at the ASH Annual Read More ›

Ascentage Pharma (6855.HK) today announced that the initial results from a global Phase II study of the company’s Bcl-2-selective inhibitor, lisaftoclax (APG-2575), as a monotherapy or in combination regimens for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL), have been selected for an oral presentation at the 64th American Society of Hematology Read More ›

Ascentage Pharma (6855.HK) today announced that it will release results from the Phase I first-in-human study of APG-1387, the company’s investigational inhibitor of apoptosis protein (IAP) antagonist, in patients with chronic hepatitis B (CHB), in an oral presentation at the 73th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). Prof. Jinlin Read More ›

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the results from a Phase I and Phase II study of olverembatinib (HQP1351) for the treatment of chronic myeloid leukemia (CML) have recently been published in the renowned oncology journal, the Journal Read More ›

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2022 interim results. During the reporting period, Ascentage Pharma remained steadfastly committed to its strategy of global innovation and made remarkable progress in clinical development and commercialization. Highlighting these results, Ascentage Read More ›

Ascentage Pharma (6855.HK) announced that the company’s lead asset, Olverembatinib (HQP1351), is selected as the number 1 in the Top Ten New Drugs in China by the 14th Health China Forum organized by People’s Daily Health APP, and Health Times, a paper affiliated with People’s Daily.  Also, the Forum selected Ascentage’s Chairman and CEO, Prof. Read More ›